Senators Cory Booker (D-NJ), Rand Paul (R-KY) Reps Madeleine Dean (D-PA) and Nancy Mace (R-SC) filed a revised bill requesting an update on the federal scheduling of “breakthrough therapies” -an FDA designation for certain treatments involving psilocybin and MDMA- towards advancing R&D and improving access for those in need, reported Marijuana Moment.
While the bill’s original version included sections calling for a simpler registration process for researching Schedule I drugs, the new “Breakthrough Therapies Act” would amend the Controlled Substances Act (CSA) to move Schedule I drugs, either breakthrough therapies or those qualifying for a …